Single Ultra-High-Dose Cholecalciferol to Prevent Vitamin D Deficiency in Pediatric Hematopoietic Stem Cell Transplantation
Wallace G, Jodele S, Myers KC, Dandoy CE, El-Bietar J, Nelson A, Teusink-Cross A, Khandelwal P, Taggart C, Gordon CM, Davies SM, Howell JC
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 23 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo clínico controlado (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2018-05-18 · Biol Blood Marrow Transplant · vol. 24 · número 9 · págs. 1856–1860
- Editorial
- Elsevier BV
- Citado
- 28 citas · más que el 88% de estudios similares · 2.3× el promedio de su campo
- Referencias
- 15 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY-NC-ND
- Áreas de investigación
- Vitamin D Research Studies · Pharmacological Effects and Toxicity Studies · Pregnancy and Medication Impact
- Palabras clave
- Medicine, Vitamin D and neurology, Transplantation, Hematopoietic stem cell transplantation, Mucositis, vitamin D deficiency, Gastroenterology, Internal medicine, Vitamin, Cholecalciferol, Surgery, Chemotherapy
- MeSH
- humans, vitamin d deficiency, cholecalciferol, transplantation conditioning, hematopoietic stem cell transplantation, adolescent, child, child, preschool, infant, female, male, calcium-regulating hormones and agents
12 autores
- Gregory H. Wallace🇺🇸Cincinnati Children's Hospital Medical Center; University of Cincinnati
- Sonata Jodele🇺🇸Cincinnati Children's Hospital Medical Center; University of Cincinnati
- Kasiani C. Myers🇺🇸Cincinnati Children's Hospital Medical Center; University of Cincinnati
- Christopher E. Dandoy🇺🇸Cincinnati Children's Hospital Medical Center; University of Cincinnati
- Javier Amin El-Bietar🇺🇸Cincinnati Children's Hospital Medical Center; University of Cincinnati
- Adam C. Nelson🇺🇸Cincinnati Children's Hospital Medical Center; University of Cincinnati
- Ashley Teusink‐Cross🇺🇸Cincinnati Children's Hospital Medical Center; University of Cincinnati
- Pooja Khandelwal🇺🇸Cincinnati Children's Hospital Medical Center; University of Cincinnati
- Cynthia B. Taggart🇺🇸Cincinnati Children's Hospital Medical Center; University of Cincinnati
- Catherine M. Gordon🇺🇸Cincinnati Children's Hospital Medical Center; University of Cincinnati
- Stella M. Davies🇺🇸Cincinnati Children's Hospital Medical Center; University of Cincinnati
- Jonathan Christian Howell🇺🇸 · autor de correspondenciaCincinnati Children's Hospital Medical Center; University of Cincinnati
Resumen
El texto original del estudio, en el idioma en que se publicó.
Vitamin D deficiency is prevalent among childhood hematopoietic stem cell transplantation (HSCT) recipients and associated with inferior survival at 100 days after transplantation. Achieving and maintaining therapeutic vitamin D levels in HSCT recipients is extremely challenging in the first 3 to 6 months after transplantation due to poor compliance in the setting of mucositis and the concomitant use of critical transplantation drugs that interfere with vitamin D absorption. We sought to evaluate the safety and efficacy of a single, ultra-high-dose of vitamin D given before childhood HSCT to maintain levels in a therapeutic range during the peritransplantation period. Ten HSCT recipients with pretransplantation 25-OH vitamin D (25OHD) level 30 ng/mL. Mean vitamin D levels were sustained at or above 30 ng/mL during the 8-week observation window. There were no electrolyte abnormalities attributed to the ultra-high-dose of vitamin D. Most patients had mildly elevated urine calcium/creatinine ratios during treatment, but none showed clinical or radiologic signs of nephrocalcinosis or nephrolithiasis. Our findings indicate that single ultra-high-oral dose vitamin D treatment given just before HSCT is safe and well tolerated in the immediate peritransplant period in children. Patients in our study were able to achieve and sustain therapeutic vitamin D levels throughout the critical period during which vitamin D insufficiency is associated with decreased overall survival. Larger prospective studies are needed to address the impact of single ultra-high-dose vitamin D treatment on HSCT outcomes.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-ND).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.